News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

Press Release

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now

Press Release

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now

News

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Read Now

Press Release

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Read Now

News

CRISPR’s cardio catch-all drives a biotech’s broad potential

February 18, 2025

PharmaVoice

Read Now

Press Release

CRISPR’s cardio catch-all drives a biotech’s broad potential

February 18, 2025

PharmaVoice

Read Now

News

Towards an AI-Driven CRISPR Future

February 11, 2025

SynBioBeta

Read Now

Press Release

Towards an AI-Driven CRISPR Future

February 11, 2025

SynBioBeta

Read Now

News

2025 predictions: Which trends are set to shape the biotech industry this year?

January 13, 2025

Labiotech

Read Now

Press Release

2025 predictions: Which trends are set to shape the biotech industry this year?

January 13, 2025

Labiotech

Read Now

Press Release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now

Press Release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now

News

DNA Island: Alameda is attracting biotechs amid an industrywide downturn

May 15, 2025

San Francisco Business Times

Read Now

News

CRISPRMED25 Virtual Event Roundup

April 8, 2025

CRISPR Medicine News

Read Now

News

From Tools to Trials: Editing Therapy Companies Pivot to Development

March 20, 2025

Genetic Engineering & Biotechnology News

Read Now

News

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Read Now

News

CRISPR’s cardio catch-all drives a biotech’s broad potential

February 18, 2025

PharmaVoice

Read Now

News

Towards an AI-Driven CRISPR Future

February 11, 2025

SynBioBeta

Read Now

Press release

Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 28, 2026

Read Now

Press release

Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction

May 21, 2026

Read Now

Press release

Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing

May 18, 2026

Read Now

Press release

Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026

April 30, 2026

Read Now

Press release

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

February 17, 2026

Read Now

Press release

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now

Publications and presentations

Publication

Engineered Allosteric Control Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

January 14, 2026

bioRxiv

Read Now

Publication

Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging

May 18, 2025

Journal of Controlled Release

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now